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Cells ofthe myelomonocytic series, which arise from a single stem cell, express
surface antigens that are either unique to granulocytes or monocytes or are
shared with cells of other hematopoietic lineages (1-11). mAbs have been used
as powerful means forthe identification ofthese antigens. Some mAbs react with
antigens present only during specific early stages of myelomonocytic differentia-
tion, while others identify more differentiated lineage-specific plasma membrane
antigens (2-4, 6, 7). mAbs have also been developed that identify proteins that
constitute several leukocyte plasma membrane receptors for fragments of the
third component of complement (8, 9). Since the same ligand is commonly
recognized by more than one class ofleukocytes, such antibodies typicallyidentify
all leukocytes that express the receptor for that particular ligand. For example,
mAbs OKM1, OKM10, and IB4 identify the polypeptide complex comprising
the human leukocyte receptor for C3bi (CR3) found on both neutrophils and
monocytes (8, 9). However, recent reports have described the production of
mAbs that immunoprecipitate proteins similar to those of the CR3 but that are
found uniquely on human neutrophils (10, 11). These findings suggested the
possibility that receptors whose ligand specificity is identical mayexhibit antigenic
and structural differences between the various classes of leukocytes.
In studies reported here, we set out to identify plasma membrane proteins of
human neutrophils that carry antigenic determinants unique to this cell type. To
increase the likelihood ofproducing mAbs to such neutrophil-specific antigens,
we used a modification of a novel immunization procedure. Mice were first
tolerized to common leukocyte antigens and then immunized with neutrophils.
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We describe the production of one mAb produced by this procedure and
demonstrate that this mAb, called BH2-C6, is specific for human neutrophils.
Combined analysis of human bone marrow cells and of the leukemic cell line
HL-60 shows that the expression of the BH2-C6 antigen during hematopoietic
differentiation is a property unique to cells committed to the neutrophil lineage.
We further show that mAb BH2-C6 interferes with the CR3 activity of these
cells, but the antigen recognized by this mAb is distinct from the neutrophil
CR3.
Materials and Methods
Animals. Female BALB/c mice (5-10 wk old) were obtained from Charles River
Breeding Laboratories (Wilmington, MA).
Preparation of Peripheral Blood Leukocytes.
￿
Polymorphonuclear (PMN)' and mononu-
clear (MN) leukocytes were isolated from heparinized (25 U/ml preservative-free sodium
heparin) bloodof healthy volunteers by dextran sedimentation followed by centrifugation
in Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, NJ) (12). Residual erythrocytes
were removedby hypotonic lysiswith 0.2% sodium chloride. Lymphocytes were separated
from monocytes by incubating the MN cells with acid-treated glass beads for 1 h at 37°C
in 50% autologous serum. The nonadherent population contained <0.5% monocytes.
Buffy coat cells were prepared as described above except the Ficoll-Hypaque step was
omitted. Purified cells were stored in HBSS (Gibco Laboratories, Grand Island, NY)
buffered to pH 7.2 with 10 mM Hepes (Sigma Chemical Co., St. Louis, MO). Viability
remained above 97%, asjudged by the trypan blue exclusion test.
Preparation ofBone Marrow Cells.
￿
Bone marrow was obtained from material removed
from the head of the femur during hip replacement surgery. The cells were washed in
HBSS containing 1 mM EDTA (Sigma Chemical, Co.), erythrocytes were removed by
lysis for 5 min at room temperature (RT) in 0.15 M ammonium chloride in 10 mM
KHCO3, and the cells were resuspended in HBSS .
Cell Lines.
￿
P3U-1 myeloma cells, a gift of Dr. J. Unkeless of The Rockefeller Univer-
sity, were grown in DME (Gibco Laboratories) and 15% heat-inactivated FCS (HIFCS;
Flow Laboratories, Inc., Rockville, MD) supplemented with 50 U/ml penicillin and 50
rug/ml streptomycin (P/S; Flow Laboratories, Inc.). HL-60 cells (13), originally obtained
from Dr. R. Gallo, National Institute of Health, Bethesda, MD, were grown in RPMI
medium (Gibco Laboratories) and 10% HIFCS supplemented with P/S.
Induction ofHL-60 Differentiation.
￿
HL-60 cells in log phase were induced to differen-
tiate by 4 d of culture in 40 mM 5,5-dimethyl-oxazolidine-2,4-dione (DMO ; Sigma
Chemical Co.) (14) or 1.5 AM cis-retinoic acid (c-RA; a gift of Dr. Pestka, Hoffman-
LaRoche Inc., Nutley, NJ) (15) or by 24-h culture in PMA (16). The degree of differen-
tiation was quantitated using the nitro blue tetrazolium (NBT) reduction assay (17).
Preparation of the Hybridoma.
￿
Female BALB/c mice were injected intraperitoneally
with 107 purified human lymphocytes. 1 d later they were injected intraperitoneally with
215 ug/g of body weight of Cytoxan (MeadJohnson Pharmaceutical, Evansville, IN) (18,
19). On days 13, 27, and 34, the mice were injected intraperitoneally with 1-2 X 107
purified human PMN. 3 d after the final boost, serum samples were obtained, and
screened by indirect fluorescence assay (IFA) on human buffy coat cells for the presence
of antibodies reactive with human PMN. The mouse chosen for cell fusion had the highest
serum titer of anti-PMN antibodies and the lowest titer of antibodies to other human
blood cells. Cell fusion was carried out according to Kohler and Milstein (20). After
fusion, the cells were cultured in 96-well flat-bottomed plates (Falcon Labware, Oxnard,
CA)in HAT medium (21) . Thecellswere then transferred to hypoxanthine and thymidine
' Abbreviations used in this paper:
￿
c-RA, cis-retinoic acid; FITC-G anti-M, FITC-goat anti-mouse
Ig; HIFCS, heat-inactivated FCS; IFA, indirect fluorescence assay; MN, mononuclear leukocyte;
PMN, polymorphonuclear leukocyte; P/S, penicillin/streptomycin; SBTI, soybean trypsin inhibitor.PYTOWSKI ET AL.
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(HT) medium, and 20 d later supernatants were tested by IFA for antibodies reactive
with PMN. Selected positive colonies were expanded and cloned in 0.55% soft agar (FMC
Corp., Marine Colloids Division, Rockland, ME) in DME with 20% HIFCS and 13%
Iscove's supplement and P/S using chick embryo fibroblasts as a feeder layer. Clone
BH2.22.11 was selected because its supernatant selectively stained neutrophils in IFA.
This clone was subcloned once, and subclone BH2-C6 was expanded for further use.
Ascites was produced by injecting i.p. 10'hybridomacellsinto pristane-primed (2,5,10,16-
tetramethyl pentadecane; Sigma Chemical Co.) BALB/c mice.
Purification ofBH2-C6.
￿
Globulin fraction of ascites was precipitated at 45% saturation
of (NH4)2SO4. Dialyzed precipitate was passed over a column of CM-Affi Gel Blue (Bio
Rad Laboratories, Richmond, CA) equilibrated with PBS. BH2-C6 was contained in the
flow-through peak.
Iodination ofAntibodies.
￿
mAb BH2-C6 was iodinated by the chloramine T method (22)
using carrier-free [1211)Na (Amersham Corp., Arlington Heights, IL). The iodinated
antibody was separated from free iodine by chromatography on coarse Sephadex G-25
(Pharmacia Fine Chemicals), dialyzed against PBS, and stored at -20°C. The specific
activity of '25I-BH2-C6 was 5-10 ACi/ug protein.
Radioimmunoassay (RIA).
￿
Purified PMN were seeded in 96-well flat-bottomed plates
at 5 x 104 cells per well. The cells were fixed for 2 h in 1% formaldehyde in HBSS,
washed, and blocked for 1 h with 1% HIFCS in HBSS (HBSS-HIFCS). The plates were
placed on ice, and dilutions of '251-BH2-C6 antibody in HBSS-HIFCS were added in
triplicate to the wells. For the determination of nonspecific binding, parallel triplicate
wells received the same dilutions of '25I-BH2-C6 containing 20 ug/well cold BH2-C6.
After 1 h, the wells were washed, the cell-associated radioactivity was solubilized with
0.1 % NP-40, and transferred to counting tubeswith Q-tips. Thedata were analyzed using
a one-sided, computer-generated, nonlinear regression.
Immunodiffusion.
￿
Immunodiffusion was performed using a commercial double immu-
nodiffusion plate (CooperBiomedical, Inc., Malvern, PA).
Gel Electrophoresis. SDS-PAGE of Igs and cellular proteins was performed using
standard methods (23). Purified cells were first treated with i mM diisopropylfluorophos-
phate (DFP; Sigma Chemical Co.) (24), washed in PBS, and lysed on ice in 1% NP-40
buffered with 10 mM Tris-HCI, pH 7.2, containing 0.9% NaCl, 0.25% sodium deoxycho-
late, 5 mM iodoacetamide, 1 mM PMSF, and 100 U/ml aprotonin (all from Sigma
Chemical Co.). The nuclei were removed by centrifugation for 1 min at 8,000 g, the
lysates were adjusted to 1% SDS and 1% 2-ME, boiled for 2 min, and the proteins were
electrophoresed on 4-11 % gradient gels.
Immunoblotting. Proteins were transferred electrophoretically from SDS-PAGE gels
onto nitrocellulose as described elsewhere (25). A blot from one set of gel lanes was
stained with 0.1 % amido black. Duplicate blots were treated with 5% wt/vol nonfat dry
milk (Carnation Co., Los Angeles, CA) dissolved in PBS (BLOTTO) (26). The blots were
incubated overnight on a shaker at 5°C with '25I-BH2-C6. Typically, 10' TCA-precipi-
table cpm were added in 80 ml BLOTTO. Blots were washed three times for 30 min in
BLOTTO, rinsed in PBS, dried, and exposed to Kodak X-Omat x-ray film at -70°C.
Attachment of Opsonized Sheep E.
￿
E were opsonized with C3bi (EIgMC3bi) or IgG
(EIgG) as described (27, 28). 5 x 104 purified human PMN in HBSS were allowed to
adhere per 12-mm glass coverslip for 15 min at 37 °C. The coverslips were placed on ice
and the cells incubated for 30 min in 25 ILI HBSS containing 2.5,ug of BSA or mAbs in
the presence or absence of 2 mg/ml soybean trypsin inhibitor (SBTI, Sigma Chemical
Co.). 2.5 x 106 of EIgMC3bi or EIgG were added in 25 ul HBSS to each coverslip. After
incubation for 1 h at 37 °C, nonbound E were removed by dipping the coverslips into
HBSS, and the cells were fixed in 2% glutaraldehyde in HBSS. The binding was
enumerated by counting cells in several fields with a x 100 objective in a phase-contrast
microscope.
Indirect Fluorescence Assay(IFA).
￿
Hybridoma supernatant screeningwas done on buffy
coat cells or purified PMN adhered to Terasaki plates (Falcon Labware). All other assays
were done with cells seeded onto 12-mm glass coverslips (Bellco Glass, Inc., Vineland,424
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NJ). For IFA on buffy coat and HL-60 cells, the coverslips were pretreated for 30 min at
RT with 50 jAg/ml poly-r.-lysine (PLL; Sigma Chemical Co.). The cells were incubated
with hybridoma culture supernatants or dilutions of primary antibody in HBSS-HIFCS
for 45 min at 2°C. Nonbound antibodies were washed off by dipping the coverslips into
ice-cold PBS-HIFCS. The cells were fixed in freshly prepared 4% paraformaldehyde
(Electron Microscopy Sciences, Fort Washington, PA) in PBS. Affinity-purified rhodami-
natedgoat anti-mouse IgM (TRITC-G anti-M IgM, u chain-specific; CooperBiomedical,
Inc.) second antibody was added for 30 min on ice. The cells were photographed on Tri-
X film (Kodak Inc., Rochester, NY) in a Zeiss Standard microscope equipped with phase
contrast and epifluorescence optics.
Flow Cytometry.
￿
Cells were incubated for I h on ice with 1 ug/ml BH2-C6 in HBSS-
HIFBS, washed by centrifugation in HBSS-HIFCS, and incubated for 30 min on ice with
a 1 :40 dilution of affinity-purified IgG fraction of goat anti-mouse Ig conjugated with
FITC (FITC-G anti-M Ig; CooperBiomedical, Inc.). The cells were washed free of
unbound antibody, and resuspended in ice-cold PBS-HIFCS. Fluorescence was analyzed
in a Becton Dickinson & Co. (Mountain View, CA) FACS IV flow cytometer equipped
with a Spectra-Physics 2-W argon-laser. Excitation was at 488.8 nm at an incident power
of 300 mW. Fluorescence emission was measured using a 530 nm long-bandpass filter
and recorded as the log of relative intensity. Data were analyzed using a Becton Dickinson
& Co. Consort 30 computer system. Sorted cells were centrifuged onto glass slides using
a cytocentrifuge (Shandon-Eliot, Inc., Camberlay, England), fixed in methanol, stained
with Wright-Giemsa stain, and photographed.
Immunoelectron Microscopy.
￿
Human PMN were incubated in suspension on ice for 1 h
with 20 ug/ml BH2-C6 in PBS-HIFCS, washed by centrifugation in HBSS-HIFCS, and
sequentially incubated on ice with a rabbit anti-mouse Ig (Miles Laboratories Inc., Elkhart,
IN) diluted 1 :20 in HBSS-HIFCS and a 1 :10 dilution of 9 nm colloidal gold prepared by
the method of Miihlpfordt (29) and derivatized with staphylococcal protein A. After
washing, cell pellets were fixed in 2% glutaraldehyde in PBS, postfixed in 1% osmium
tetroxide, dehydrated in ethanol, and embedded in Epon. Thin sections were stained in
uranyl acetate, and examined on a Phillips 300 TEM .
Results
Preparation and Characterization of the BH2-C6 Antibody.
￿
mAb BH2-C6 is an
IgM with K light chains, as demonstrated by Ouchterlony immunodiffusion with
rabbit antisera specific for mouse y and K chains. Upon complete reduction and
analysis by SDS-PAGE, the molecule separates into heavy and light chains of 80
and 27 kD, respectively (data not shown).
Specificity of the mAb BH2-C6 for Human Peripheral Blood Neutrophils.
￿
The
reactivity of BH2-C6 with human cells was examined by IFA. Fig. I shows the
resulting fluorescence pattern on living human leukocytes stained with 5 kg/ml
BH2-C6. Purified neutrophils (Fig. I c) stain in a bright, uniform circular pattern
(Fig. 1 d). This staining with BH2-C6 is characteristic of >99% of unspread
neutrophils. When buffy coat cells were examined, only the neutrophils were
found to stain with BH2-C6 (Fig. 1f). Unstained cells visible in the phase-contrast
micrograph of Fig. I e include lymphocytes (arrowheads), monocytes (large ar-
rows), and platelets (small arrow). In the absence of BH2-C6, there is no fluores-
cent staining (Fig. 1 b) of purified PMN (Fig. 1 a). Further, BH2-C6 failed to
stain human erythrocytes, foreskin fibroblasts, as well as frozen sections of lymph
nodes . mAb BH2-C6 does not react with neutrophils of mice, rats, and macaque
monkeys (data not shown).
BH2-C6 is cytotoxic. Incubation of BH2-C6-coated neutrophils with fresh
guinea pig complement at 37°C results in the lysis of >99% of the cells.FIGURE 1 .
￿
Indirect fluorescence ofhuman peripheral cells stained with mAb BH2-C6 . PMN
(a-d) and buffy coat leukocytes (e andf) were purified, allowed to adhere to PLL-coated
coverslips, and processed as described in the Materials and Methods section . No staining of
thePMN canbe seen in the absence ofmAbBH2-C6 (b) . Addition ofthemAb BH2-C6 results
in the appearance of ring fluorescence of the neutrophils (d) . Treatment of the buffy coat
cells with mAb BH2-C6 results in fluorescence staining limited to neutrophils (f) . There is no
fluorescence on the plasma membranes of monocytes (large arrow), lymphocytes (arrowheads),
and platelets (small arrow) that can be identified in the phase-contrast photomicrograph shown
in e . The photomicrographs were taken with a x 100 (a-d) and x 40 (e andf) objectives . (a,
c, and e) Phase-contrast ; (b, d, andf) corresponding epifluorescence images .
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Lack of Reactivity of B112-C6 with Human Eosinophils.
￿
In IFA analysis, we
consistently observed that mAb BH2-C6 does not stain eosinophils in the ring
pattern characteristic of plasma membrane antigens. However, the presence of
an autofluorescent substance in the granules of eosinophils made it difficult to
determine, on the basis of IFA, whether these cells express the surface antigen
recognized by mAb BH2-C6 . To further investigate the specificity of mAb BH2-
C6 for human neutrophils, we used immunogold electron microscopy . Purified
PMN in ice-cold HBSS-HIFCS were sequentially reacted with mAb BH2-C6,
rabbit anti-mouse Ig, and colloidal gold derivatized with protein A. Fig. 2, b and
c, shows binding of the gold particles around the entire periphery of the
neutrophil. By contrast, the plasma membrane of the eosinophil (Fig. 2c),
identified by the presence of the crystalloids in the granules (arrowheads), has no
bound gold particles. Of five eosinophils observed in thin sections, none stained
with the BH2-C6-containing gold immunocomplex, while virtually all neutro-
phils observed were stained.
When observed at higher magnification (Fig. 2d), the linear deposition of gold
on the surface of the neutrophil indicates that the BH2-C6 antigen is uniformly
distributed in the plasma membrane of this cell with no apparent clustering or
patching. The high densityof the deposited gold suggests the presence of a large
number of BH2-C6 antigenic sites on the neutrophil plasma membrane. In the
absence of BH2-C6, the plasma membrane of neutrophils is completely devoid
of the gold particles (Fig. 2a).
Identification oftheNeutrophil Molecule Recognized by BH2-C6.
￿
The biochemical
nature of the molecule recognized by BH2-C6 was investigated with immuno-
blotting of PMN proteins separated by SDS-PAGE under reducing conditions.
Separated proteins from lysates of 107 PMN and mononuclear cells were trans-
ferred electrophoretically onto nitrocellulose, and the band containing the epi-
tope recognized by BH2-C6 was detected with 1251-labeled BH2-C6. Fig. 3, lane
4, shows that 1251-BH2-C6 binds to a PMN polypeptide band with an average
molecular mass of 157 ± 12 kD (BH2-Ag). The specificity of this binding was
shown by the inability of 1251-BH2-C6 to bind to PMN proteins in the presence
of 50-fold excess of unlabeled antibody (lane 5). The absence of binding of 12s1-
BH2-C6 to proteins of mononuclear cells (lane 3) confirms that the BH2-Ag is
not present in these cells.
Quantitation ofBinding of "5I-BH2-C6 to Human PMN.
￿
Binding of 1251-BH2-
C6 to human PMN is saturable, with a half-saturating concentration of ^-325 ng
antibody per 5 x 10' (Fig. 4) . Computer-generated nonlinear fit of the data gives
an estimate of 19.5 ng of antibody bound to this number of cells at saturation,
corresponding to 214,000 molecules of 1251-BH2-C6 bound per cell.
Effect ofmAbBH2-C6 on the Neutrophil Receptorfor C3bi (CR3).
￿
mAbs reported
to be neutrophil specific (10-1 1) have been shown to immunoprecipitate proteins
similar to those of the CD 11 /CD18 complex of leukocyte antigens. These
antigens comprise a family of three dimeric proteins, CD1 la/CD18 (also known
as LFA-1), CD 1 lb/CD18 (also known as Mac-1 or the C3bi receptor [CR3]), and
CD 1 lc/CD18 (also known as p150,95) (8, 9). Since the BH2-Ag has a molecular
weight closely resembling that of CD 11 b and CD 11 c, we tested the ability of thePYTOWSKI ET AL .
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FIGURE 2.
￿
Immunoelectron microscopy of humanPMN stained withmAb BH2-C6 . Purified
PMN were sequentially stained with mAb BH2-C6, rabbit anti-mouse Ig, and protein A-
derivatized 9nM colloidal gold andprepared for electron microscopy as described in Materials
and Methods . Control samples were processed in the absence of mAb BH2-C6. (a) Control
cells . (b-d) Samples processed in the presence ofmAb BH2-C6 . The arrowheads in c indicate
the characteristic crystalloids found in the granules of eosinophils (E) . Magnifications: a,
x 14,200 ; b, x 12,600 ; c, x 14,600 ; d, x 19,400 .
mAb BH2-C6 to interfere with binding of sheep erythrocytes opsonized with
C3bi to PMN.
Efficient binding of C3bi-opsonized E to phagocytes occurs only at tempera-
tures above 30°C (30) . It is possible that during incubation at this temperature,
the release of endogenous proteases by the neutrophils may lead to loss of the428
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FIGURE 3 . Identification of the antigen recog-
nized by themAb BH2-C6 . Solubilized proteins of
PMN and mononuclear cells were separated by
SDS-PAGE on 4-12% gels using 10' cells per lane .
The separated proteins were blotted onto nitro-
cellulose as described in Materials and Methods.
Parallel blotswere stained with amido black (lanes
1 and 2) or incubated with '251-BH2-C6 and au-
toradiographed (lanes 3-5) . (Lanes 1and 3) Mono-
nuclear cells . (Lanes 2, 4, and 5) PMN. (Lane 5)
PMN blots reacted with '251-BH2-C6 in the pres-
ence of 50-fold excess of unlabeledBH2-C6.
FIGURE 4 .
￿
Binding characteristics of '251-BH2-C6 . Purified PMN
were seeded at 5 x 10 4 per well in 96-well plates and incubated
with increasing amounts of '251-BH2-C6 . Nonspecific binding was
determined by incubating the cells with 1251-BH2-C6 in the pres-
ence of 20 ug/well of unlabeledmAbBH2-C6 . Computer-generated
nonlinear fit of specific binding of 1251-BH2-C6 to PMN gives an
estimate of 19.5 ng of 1251-BH2-C6 bound to 5 x 10 4 cells at
saturation .
C3bi ligand or the CR3 . Therefore, the binding experiments were done in the
absence or presence of the serine protease inhibitor SBTI .
The addition of mAb BH2-C6 reduced the attachment index for EIgMC3bi
to 2% of the BSA control, but this effect was partially reversed (to 41% of
control) by the addition ofSBTI (Table I) . By contrast, the addition of the mAb
BH2-C6 had no effect on the ability of the PMN to bind EIgG (Table 1) . Control
experiments showed that the binding of EIgG was completely inhibited by the
presence of the anti-FcR mAb 3G8 (31), and this inhibition was not reversed by
SBTI .
Three possibilities are suggested by these observations : (a) BH2-C6 may bind
to CR3; (b) BH2-C6 may bind to a molecule physically associated with CR3 and
thus sterically block ligand binding; (c) BH2-C6 may trigger the release of
proteolytic enzymes that cleave C3bi or its receptor . The following data rule out
the first two possibilities .
BH2-C6 Does Not Recognize Antigens in the CD18 Complex .
￿
We examined the
expression of BH2-C6 Ag on PMN from a patient congenitally deficient in allTABLE I
TheEffect of mAb BH2-C6 on the Attachment ofOpsonixed Sheep
Erythrocytes by Human PolymorphonuclearLeukocytes
Treatment*
BSA 848
BH2-C6 20
3G8 642
* BSAand mAbs BH2-C6 and 3G8 at 100,ug/ml.
Attachment index is defined as: [(Number of E attached)/(total number
of PMN)] x (percent of PMN with attached E). These data are from a
representative experiment; two additional experiments gave similarre-
sults.
¢SBTI at 2 mg/ml.
C
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FIGURE 5.
￿
Cytofluorimetric analysis of mAb BH2-C6 reactiv-
itywith neutrophils of a patient deficient in theCD18 complex.
Purified PMN from a patient with congenital absence of CD18
and from an age-matched normal subject were incubated with
5,ug/ml mAb BH2-C6 or the anti-CD18 mAb IB4 followed by
FITC-G anti-M Ig. (A) Fluorescence distribution of purified
PMN from the normal subject stained with mAb IB4. (B) The
pattern of fluorescence obtained by staining PMN from CD 18-
deficient patient with mAb IB4. (C) Fluorescence pattern ob-
tained by staining thepatient'sPMNwith mAb BH2-C6. Dotted
line shows the fluorescence distribution of the patient's PMN
when mAb BH2-C6 was omitted.
three members of the CD18 complex (Wright, S. D., Z. Chad, and L. Kabbash,
manuscript in preparation) . mAb IB4 (directed against CD18, reference 8) stains
normal PMN brightly (Fig. 5a), but no staining above background is detected
on PMN from the patient (Fig. 5b). In contrast, the PMN from the patient react
normally with BH2-C6 (Fig. 5c). These data were confirmed by measuring the
binding of radioiodinated 1114 and BH2-C6 to purified PMN. Binding of IB4
was <0.2% of that on control cells, while binding of BH2-C6 was 80% as great
as control (data not shown). These data demonstrate that BH2-C6 does not
I
EIgMC3bi
+SBTI1 -SBTI
EIgG
+SBTI
100 926 100 469 100 501 100
2 379 41 502 107 441 88
76 1014 109 2 <1 4 <1430
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FIGURE 6 .
￿
Lack of cocapping of the BH2-Ag andthe CR3. Purified PMN were sequentially
incubated in suspension on ice with 20 fag/ml mAb OKM1 and FITC-G anti-M IgG and
washed by centrifugation in ice-cold PBS . The cells were resuspended in I ml of HBSS at
37 °C for 5 min to allow capping, cooled to 5°C with 40 ml of ice-cold PBS and allowed to
adhere on ice to 12 mm coverslips coated with PLL . The cells were then fixed in 4%
paraformaldehyde and further sequentially incubated on ice with 5 kg/ml mAb BH2-C6 and
TRITC-G anti-M IgM . Photomicrographs were taken with a x 63 objective . (A) Phase-
contrast ; (B) mAbOKMI ; (C) mAb BH2-C6 .
recognize any members of the CD18 family and thus does not recognize the
CR3 .
BH2-C6 Ag Does Not Cocap with CR3 .
￿
Purified human PMN were sequentially
incubated on ice in suspension with the anti-CR3 mAb OKM1 (9) and FITC-G
anti-M IgG . The cells were warmed to 37°C for 5 min to allow the capping of
the OKM1-CR3 complex, cooled to 5'C, and adhered to PLL-coated coverslips
at 5'C . The cells were fixed in paraformaldehyde, incubated sequentially with
mAbBH2-C6 andTRITC-G anti-M IgM (Ec chain-specific), and photographed .
As can be seen in Fig . 6, the BH2-Ag does not segregate into the OKM1-a
E
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FIGURE 7.
￿
FACS analysis of
mAb BH2-C6 binding to hu-
man bone marrow cells. Bone
marrow cells were serially in-
cubated with mAb BH2-C6
and FITC-G anti-M Ig and
sorted as described in Mate-
rials and Methods. (A and B)
Distribution of fluorescence
intensity and settings of the
gates for sorting andanalysis.
(C and D) Forward and right
angle light scatter plots of
gated fluorescence-positive
cell populations.
mediated surface caps. This result demonstrates that the BH2-Ag isnot physically
associated with the CR3 in the plasma membrane.
Expression ofBH2-Ag by Myelomonocytic Precursor Cells in Normal Human Bone
Marrow. The specificity of mAb BH2-C6 for a plasma membrane antigen
unique to human peripheral blood neutrophils prompted us to investigate the
expression of this antigen during myelopoiesis. Cytofluorometric analysis of
human bone marrow cells was used in conjunction with histochemical staining
and differential counting of sorted cells to establish the distribution of BH2-Ag
during neutrophilic differentiation.
5 x 106 human bone marrow cells were stained for I h on ice with 1 Ag/ml
mAb BH2-C6 and FITC-G anti-M Ig. In all samples examined, the cellular
distribution based on light scatter and differential cell counts was characteristic
ofnormal bone marrow. Analysis offluorescence shows a cell population negative
for BH2-C6-mediated fluorescence and two populations of intermediate and
high fluorescence intensity (Fig. 7, A and C). Together, the positive populations
contained 65% of the bone marrow cells analyzed. The cells making up these
two populations were sorted using fluorescence intensity gating shown in Fig. 7,
A and C. Differential counts were performed on cytocentrifuge preparations of
the sorted cells after Wright-Giemsa staining (Table II). The cells in the brightly
fluorescent population (Fig. 7C, gate 2) have light scatter characteristics oflate-
stage granulocytic precursors and ofmature granulocytes (Fig. 7D) . The popu-
lation ofcells characterized by intermediate-intensity fluorescence (Fig. 7A, gate
1) hasa light-scatter distribution (Fig. 7B) thatpartially overlaps that ofthe high-
intensity population. However, the bone marrow cells gated in panel A include,432
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TABLE II
Cytofluorimetric Analysis ofNormal Human Bone
Marrow CellsBased on Reactivity with mAb BH2-C6
* Monocytes and lymphocytes.
Pronormoblasts, basophilic normoblasts, polychromatic normoblasts and
orthochromatic normoblasts.
Plasmacytes and megakaryocytes.
in addition, a subpopulation whose light-scatter distribution (Fig. 7B) is charac-
teristic of cells in early stages of myelopoiesis (32).
All myeloblasts observed were negative for BH2-Ag. The earliest granulocytic
precursors found to be fluorescence-positive for BH2-Ag are the promyelocytes
(Table II). As the cells mature into myelocytes, there is a continued, low level
expression of BH2-Ag. During this stage, there occurs a significant increase in
BH2-Ag surface expression as evidenced by the division of myelocytes into the
intermediate and high fluorescence intensity populations. The high fluorescence
intensity population is composed of metamyelocytes, banded, and segmented
neutrophils.
Expression ofBH2-Ag on HL-60 Cells During Neutrophilic Differentiation.
￿
In an
attempt to confirm in vitro the results of bone marrow analysis, we examined
the expression of BH2-Ag on the human myeloblastic-promyelocytec cell line
HL-60 (13). This cell line can be induced to further differentiate along the
granulocytic lineage by treatment with various pharmacological agents. In the
first experiment, we examined the binding of 1251-BH2-C6 to HL-60 cells
cultured in the absence or presence of 40 mM DMO (14) or 1.5 uM c-RA (15).
Afteran incubation period of4 d, the cells were seeded in 96-well, flat-bottomed
plates pretreated with 50 /Ag/ml PLL to promote equal adherence ofcontrol and
induced cells. A saturating dose of37 ng 1251-BH2-C6 and 250 ng cold BH2-C6
(see Fig. 4) was added to each well for 1 h on ice and the cells were processed as
described in Materials and Methods. Table III shows the results of this experi-
ment. HL-60 cells that were cultured in RPMI alone bind only 2.3% of the
amount of 1251-111-12-C6 bound by an equivalent number of PMN. Incubation of
Cells Unsorted
Distribution
according
Negative
of cells sorted
to fluorescence
Low High
intensity intensity
Myeloblasts 1 7 0 0
Promyelocytes 6 2 26 0
Myelocytes 19 0 55 15
Metamyelocytes 16 0 10 28
Bands 14 0 1 22
Neutrophils 14 0 0 35
Eosinophils 3 2 6 0
Basophils 1 0 0 0
Mononuclear cells* 16 76 2 2
Erythroidcells* 9 12 0 0
Others4 2 1 0 0PYTOWSKI ET AL.
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TABLE III
Effect ofNeutrophilic Differentiation on the Bindingof '25I-BH2-C6
to HL-60 Cells
Discussion
* 5 x 10' cellsper well.
$Specific cpm were calculated by subtracting the cpm bound in the
presence of 50-fold excess of unlabeled mAbBH2-C6.
¢Standard errorof the mean.
the cells with c-RA results in an 8.5 times higher binding of 1251-BH2-C6.
Similarly, incubation with DMO increases the binding of 1251-BH2-C6 by 10 .7
times.
Parallel cell samples were evaluated for NBT reduction. The results in Table
III show that only 8% of HL-60 cells cultured in RPMI alone are capable of
reducing NBT. By contrast, when HL-60 cells are incubated in the presence of
c-RA, the percentage of cells reducing NBT increases 3.4-fold. The correspond-
ing increase for cells incubated with DMO is 5.1-fold.
The level of 1251-BH2-C6 binding to HL-60 cells induced with c-RA or DMO
is only 20 and 25%, respectively, of that binding to PMN (Table III). Thus, it
was important to establish whether the incubation of HL-60 cells with these
agents results in the induction of BH2-Ag expression in a subpopulation of these
cells. To address this question, we used indirect immunofluorescence to deter-
mine the percentage of BH2-Ag'' HL-60 cells. As shown in Fig. 8, only very few
(<4%) BH2-Ag'' cells are found in an HL-60 cell population that was incubated
in RPMI alone (Fig. 8B). By contrast, 82% of cells induced with DMO (Fig. 8D)
and 90% of cells induced with c-RA (Fig. 8F) express the BH2-Ag.
These results show that the treatment with inducers of granulocytic differen-
tiation, DMO or c-RA, stimulates the HL-60 cells to initiate expression of BH2-
Ag. The appearance of this antigen correlates well with cellular changes which
indicate granulocytic differentiation: alteration of cell morphology (Fig. 8, A, C,
and E) and the ability to reduce NBT. In contrast, the exposure of HL-60 cells
to TPA, an inducer of monocytic differentiation, failed to evoke the appearance
of BH2-Ag (data not shown).
This report describes an mAb that exhibits specificity for human peripheral
blood neutrophils and for several stages of differentiation of these cells. Analysis
of cells by immunofluorescence (Fig. 1) clearly shows that the reactivity of mAb
BH2-C6 is restricted to PMN. In numerous assays with blood of several donors,
BH2-C6 staining of monocytes, lymphocytes, erythrocytes, or platelets was never
observed. Furthermore, in analysis by immunoelectron microscopy, we found no
Treatment Specific Cells
Cells* of cells cpm bound* reducing
NBT
PMN 0 15,960 t 1,055¢ ND
HL-60 0 368 ± 143 8
HL-60 1.5,uM c-RA 3,136t 51 27
HL-60 40 mM DMO 3,926 t 204 41434
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FIGURE 8 .
￿
Expression of BH2-Ag by HL-60 cells . HL-60 cells were grown for 4 d before
analysis in culture medium alone (A andB) and in medium containing DMO (C and D) or c-
RA (E and F) . For analysis, the cells were seeded on PLL-coated glass coverslips, sequentially
incubated with mAb BH2-C6 and TRITC-G anti-M IgM, fixed and photographed using a
X 63 objective. (A, C, and E) Phase contrast . Note the increase in cell spreading and the
appearance of dense cytoplasmic granules in C and E. (B, D, and F) Corresponding fluores-
cence.PYTOWSKI ET AL.
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BH2-C6-mediated staining of eosinophil plasma membranes under conditions
in which all the neutrophils observed showed surface staining (Fig. 2). The
uniform distribution of the gold-containing immune complexes on the plasma
membrane ofthe neutrophils (Fig. 2) correlates well with the uniform pattern of
fluorescence that is characteristic ofBH2-C6 staining. This finding demonstrates
that BH2-Ag is not located in membrane clusters such as those reported for the
PMN type 1 complement receptor (33).
Analysis by immunoblotting of total cellular proteins separated from PMN
and mononuclear cells under reducing conditions shows that the molecule
recognized by mAb BH2-C6 is a single protein of 157 kD. The width of the
band seen on autoradiographs (157 ± 12 kD) suggests that BH2-Ag may be
heterogeneously glycosylated (Fig. 3). The lack of binding of 1251-BH2-C6 to
proteins of mononuclear cell lysates indicates that monocytes and lymphocytes
do not possess intracellular BH2-Ag or other proteins that carry the BH2-C6-
specific determinant.
Binding of mAb BH2-C6 to neutrophils significantly reduces attachment of
C3bi-coated erythrocytes to these phagocytes, thus suggesting an association of
the BH2-C6 Ag with CR3. We find, however, that the Ag recognized by BH2-
C6 is not expressed on CR3 (CDIIb/CD18), nor on the structurally related
CDlla/CD18 or CDllc/CD18 molecules. Cells from a patient deficient in all
three members ofthe CD18 complex reactwell with BH2-C6 (Fig. 5). We further
observed that the BH2-C6 Ag does not cocap with CR3 (Fig. 6), indicating that
it is not associated with CR3 in the plasma membrane.
An explanation for the effects ofBH2-C6 on CR3 function is suggested by the
observation that its inhibitory effects are suppressed by high concentrations of
protease inhibitor (Table I). Thus, BH2-C6 may trigger the release of proteases
that cleave C3bi or its receptor. Two ofthe neutrophil serine proteases, elastase
and cathepsin G (37), have been shown by others to convert C3bi to Cad, which
is not recognized by CR3 (34). Stimulation ofsecretion ofendogenous proteases
by antibodies to cell surface proteins has also been reported (35, 36). While the
function of BH2-C6 Ag is still obscure, our data suggest that this antigen may
function to trigger secretion by PMN. Studies to examine this possibility are
currently under way.
Several mAbs have been described in recent years that appear to be specific
forhumangranulocytes (10, 11, 39-41). Frequently, these mAbsrecognize sugar
sequences on glycoproteins and glycolipids (10, 39). One highly antigenic oligo-
saccharride, lactose-N-fucopentose III (5) is the epitope of the mAb PMN-7C3
(10) and the AHN series of human granulocyte-specific mAbs (40). Although
the exact nature of the epitope recognized by mAb BH2-C6 remains to be
defined, we believe that mAb BH2-C6 recognizes a structure distinct from this
oligosaccharride. This conclusion is based on the absence of BH2-C6 reactivity
with uninduced HL-60 cells and human myeloblasts, both of which express this
oligosaccharride antigen (39, 42). Furthermore, mAb BH2-C6recognizes asingle
neutrophil polypeptide, while mAbs AHN 1-4 identify two proteins with iden-
tical antigenic determinants (40).
The BH2-Ag molecule is expressed on the plasma membrane of all the cells
committed to neutrophilic differentiation starting with the promyelocyte. In all436
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bone marrow samples analyzed by cytofluorimetry, the myeloblasts were identi-
fied only in the fluorescence-negative population . This correlates well with the
finding that the human cell line HL-60 is also negative for BH2-Ag . These cells
are arrested in the myeloblastic-promyelocytic stage of development but can be
induced to further differentiate along granulocytic or monocytic lineages (13,
17) . Upon induction with c-RA or DMO, 60-90% of HL-60 cells attain the
morphological, enzymatic, and functional characteristics of myelocytes (15-16
and this paper) . Based on our finding that the myelocytes in cytofluorimetric
analysis fall predominantly into the fluorescent fraction of intermediate intensity,
it could be expected that c-RA or DMO-induced HL-60 cells would express
relatively low levels of BH2-Ag as compared with mature neutrophils . In fact,
exactly this finding was obtained as shown by RIA (Table III) and IFA (Fig . 8) .
It should be noted that the percentage of DMO and c-RA-induced HL-60 cells
that express BH2-Ag is significantly greater than the percentage of these cells
capable of reducing NBT . This suggests that the expression of BH2-Ag is an
earlier indicator of the granulocytic differentiation of these cells than the ability
to generate the superoxide anion .
During the myelocytic stage, there is a significant increase in the plasma
membrane expression ofBH2-Ag . This is shown by the appearance of myelocytes
in the high fluorescence intensity fraction of bone marrow cells sorted by
cytofluorimetry . This increase, therefore, occurs at the time when the mitotic
divisions cease and the cells initiate maturation into segmented neutrophils . At
this stage of neutrophilic development, there is also a significant increase in the
expression of the plasma membrane receptors for complement (38), Fc (38), and
chemotactic peptides (43), all of which are critical for the function of mature
neutrophils. The role played by the BH2-Ag in the biology of the human
neutrophil is currently being investigated .
Summary
We have used mice selectively tolerized to antigens of human lymphocytes by
treatment with cyclophosphamide to raise an mAb, BH2-C6, that reacts with a
plasma membrane antigen specific for human neutrophils . This specificity is
demonstrated by indirect immunofluorescence microscopy, cytochemical analysis
of fluorescence-positive and -negative cell populations separated by flow cytom-
etry, and by the selective, complement-mediated killing ofmAb BH2-C6-treated
neutrophils. Additional evidence for the neutrophil specificity ofmAb BH2-C6
is shown by immunoelectron microscopy, which demonstrates a lack of reactivity
with human eosinophils . Immunoblotting of SDS-PAGE-separated proteins of
polymorphonuclear leukocytes with ' 251-labeled BH2-C6 identifies protein with
an average molecular mass of 157 kD . Binding studies show that, at saturation,
neutrophils bind 214,000 molecules of '25I-BH2-C6 per cell .
Addition of mAb BH2-C6 to neutrophils significantly reduces the number of
C3bi-opsonized sheep erythrocytes (EIgMC3bi) bound by these cells. This reduc-
tion is partly reversed by the presence of soybean trypsin inhibitor (SBTI),
indicating that at least one part of this inhibition is due to BH2-C6-stimulated
secretion ofa serine protease that may affect ligand binding .
Cytochemical analysis of normal human bone marrow cells sorted by cytofluo-PYTOWSKI ET AL.
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rimetry identifies the promyelocyte as the precursor cell that first expresses BH2-
Ag on the plasma membrane. Using the leukemic cell line HL-60, we demonstrate
that only inducers of granulocytic differentiation, cis-retinoic acid, and dimeth-
yloxazolidine stimulate the expression of BH2-Ag. These results show that the
expression of BH2-Ag during myelomonocytic differentiation is a property
uniquely possessed by cells committed to the neutrophilic lineage.
We gratefully acknowledge Drs. Judith Woodruff, James Quigley, George Ojakian, and
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